The hunter syndrome treatment market is anticipated to grow with a CAGR of ~5.4% over the forecast period of 2019-2028. According to a study published by Insure Insights on the hunter syndrome treatment market, the increasing number of patients and rise in the government initiatives to increase the awareness associated with the hunter syndrome treatment are some of the driving factors for the growth of the market.  Additionally, the rise in the investments in the development of drugs by pharmaceutical companies is considered as another factor driving the growth of the market across the globe.

Top Driver: Increasing Government Initiative and Increasing Number of Patient is Expected to Drive the Hunter Syndrome Treatment Market

Hunter Syndrome is a very rare, inherited genetic disorder which occurs due to missing or malfunctioning enzyme. The basic functionality of these enzymes is to break down certain complex molecules. However, due to the loss of these enzymes, the complex molecules hamper the abilities of the human body including permanent, progressive damage affecting appearance, organ function, mental development, and physical abilities. The rise in the growth of the patients across the globe is one of the major factors driving the growth of the market. For, instance, 970 patients were enrolled with the disorder in 2014 under the Hunter Outcome Survey (HOC), which eventually reached 1195 patients in 2017.

Furthermore, the National Institute of Health (NIH) in 2018 published data which states that Hunter syndrome affects around 1 in 160,000 males globally. Additionally, it also states that the risk of developing this disease low among women because they inherit two X chromosomes and one of them can provide a functioning gene if the other X chromosome is defective. However, in men, there is no other X chromosome that can function in place of the defective one.

Early Adoption of Enzyme Replacement Therapy (ERT)Contribution to Growth of Global Hunter Syndrome Treatment Market  

Based on treatment type, the market is categorized into hematopoietic stem cell transplant (HSCT), enzyme replacement therapy (ERT), and others. Currently, the enzyme replacement therapy (ERT) dominates the market by holding the largest share based on treatment type and is expected to dominate in the near future due to the early adoption of this treatment type. Additionally, this type of treatment also increases the concentration of the missing enzyme within an individual’s body, leading to improves the cellular metabolic processes.

Based on end-users, the global hunter syndrome treatment market has been segmented as hospitals, specialty clinics, and others. The hospitals account for the largest share in the end-users segment due to the adoption of advanced treatment and well equipped medical facilities. Additionally, the presence of expertise and increasing R&D facilities within the premise is also boosting the growth of the market.

Rising Investments in Healthcare Industry in North America Market

North America has developed countries such as the US and Canada that have well-established healthcare infrastructure which is one of the major factors driving the growth of the hunter syndrome treatment market. Further, the rise in the awareness among the individuals in the region, rising investments, and funding in the R&D activities in the region is propelling in the growth of the market in the region.  Similarly, the reimbursement policies in the US for expensive drugs such as ELAPRASE are also contributing to the growth of the market. The presence of various companies such as ArmaGen, Inc., RegenxBio Inc., and others are investing in the development of drugs for the hunter syndrome treatment market.

Players to Focus on Development of New & Advanced Drugs for Hunter Syndrome Market

The global hunter syndrome treatment market is expected to grow with a significant CAGR due to presence of various companies present including Takeda Pharmaceutical Company Limited, GC Pharma, JCR Pharmaceuticals Co Ltd., Sangamo Therapeutics, Inc., and others are contributing in the growth of the market by developing new drugs and treatment methods.

Takeda Pharmaceutical Company Limited: In April 2019, the company acquired Shire Plc. to increase its market presence and sell ELAPRASE drugs for the hunter syndrome treatment market. This acquisition leads to strengthens the company’s hold on the market.

GC Pharma: April 2019, GC Pharma signed a licensing agreement with Clinigen Group plc to distributing commercialize Hunterase in Japan with the help of  Clinigen Group plc. This partnership leads to the geographical expansion of GC Pharma for the hunter syndrome market

Scope of the Report

By Treatment

• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplant (HSCT)
• Others

By Route of Administration

• Intravenous
• Intracerebroventricular (ICV)/ Intrathecal

By End-User

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.